These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 39158817)
1. LI-RADS v2018 category and imaging features: inter-modality agreement between contrast-enhanced CT, gadoxetate disodium-enhanced MRI, and extracellular contrast-enhanced MRI. Agnello F; Cannella R; Brancatelli G; Galia M Radiol Med; 2024 Nov; 129(11):1575-1586. PubMed ID: 39158817 [TBL] [Abstract][Full Text] [Related]
2. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features. Wang D; Zhang Y; Lyu R; Jia K; Xu PJ Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217 [TBL] [Abstract][Full Text] [Related]
3. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI. Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175 [TBL] [Abstract][Full Text] [Related]
4. Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System. Yang J; Jiang H; Xie K; Bashir MR; Wan H; Huang J; Qin Y; Chen J; Lu Q; Song B Eur J Radiol; 2022 Sep; 154():110397. PubMed ID: 35696735 [TBL] [Abstract][Full Text] [Related]
5. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS. Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620 [TBL] [Abstract][Full Text] [Related]
6. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis. Lee S; Kim YY; Shin J; Roh YH; Choi JY; Chernyak V; Sirlin CB Eur Radiol; 2024 Mar; 34(3):1502-1514. PubMed ID: 37656177 [TBL] [Abstract][Full Text] [Related]
7. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients. Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914 [No Abstract] [Full Text] [Related]
8. Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease. Cao J; Shon A; Yoon L; Kamaya A; Tse JR Eur Radiol; 2024 Dec; 34(12):7622-7631. PubMed ID: 38951191 [TBL] [Abstract][Full Text] [Related]
9. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study. Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029 [TBL] [Abstract][Full Text] [Related]
10. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120 [TBL] [Abstract][Full Text] [Related]
11. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma. Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054 [TBL] [Abstract][Full Text] [Related]
12. Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI. Xing F; Zhang T; Miao X; Lu J; Du S; Jiang J; Xing W Abdom Radiol (NY); 2023 Dec; 48(12):3703-3713. PubMed ID: 37740759 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma. Shahbazian H; Birnbaum J; Burns PJ; Shabanan SH; Kanmaniraja D; Reinus J; Kamel I; Sirlin CB; Chernyak V Abdom Radiol (NY); 2023 Dec; 48(12):3696-3702. PubMed ID: 37725110 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of CT versus MRI Liver Imaging Reporting and Data System category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies. Kim YY; Lee S; Shin J; Son WJ; Roh YH; Hwang JA; Lee JE Eur Radiol; 2022 Oct; 32(10):6723-6729. PubMed ID: 35849177 [TBL] [Abstract][Full Text] [Related]
15. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features. Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321 [TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416 [TBL] [Abstract][Full Text] [Related]
17. The comparison of contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI LI-RADS for nodules ≤2 cm in patients at high risk for HCC: a prospective study. Qin Z; Zhou Y; Zhang X; Ding J; Zhou H; Wang Y; Zhao L; Chen C; Jing X Front Oncol; 2024; 14():1345981. PubMed ID: 38774417 [TBL] [Abstract][Full Text] [Related]
18. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947 [TBL] [Abstract][Full Text] [Related]
19. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS. Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659 [TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. Min JH; Kim JM; Kim YK; Cha DI; Kang TW; Kim H; Choi GS; Choi SY; Ahn S Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2091-2100.e7. PubMed ID: 31843599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]